Technical Analysis for EPZM - Epizyme, Inc.

Grade Last Price % Change Price Change
grade D 17.51 2.28% 0.39
EPZM closed down 2.45 percent on Monday, June 1, 2020, on approximately normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Down
Historical EPZM trend table...

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 2.28%
MACD Bearish Signal Line Cross Bearish 2.28%
Bollinger Band Squeeze Range Contraction 2.28%
BB Squeeze Started Range Contraction 2.28%
Inside Day Range Contraction 2.28%
Down 3 Days in a Row Weakness 2.28%
Down 4 Days in a Row Weakness 2.28%
Fell Below 20 DMA Bearish -0.23%
200 DMA Support Bullish -0.23%
50 DMA Support Bullish -0.23%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Epizyme, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, planning, and commercialization of various personalized therapeutics for the treatment of patients with genetically defined cancers. Its principal product candidates under development include EPZ-5676, an intravenously administered small molecule inhibitor of DOT1L that is in Phase I clinical trials for the treatment of mixed lineage rearranged leukemia (MLL-r); and EPZ-6438, an orally available small molecule inhibitor of EZH2 for the treatment of non-Hodgkin lymphoma patients caused by an oncogenic point mutation in EZH2. The company has strategic collaboration and license agreements with Celgene Corporation and Celgene International Sàrl, as well as Glaxo Group Limited to discover, develop, and commercialize small molecule HMT inhibitors; and Eisai Co., Ltd. (Eisai) to license its EZH2 program. It also has a companion diagnostic collaboration with Abbott Molecular Inc. for the development of a companion diagnostic to identify patients with the MLL-r genetic alteration targeted by EPZ-5676; and with Roche Molecular Systems, Inc., as well as with Eisai for the development and commercialization of a companion diagnostic for use with EPZ-6438 product candidate. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Biotechnology Life Sciences Cancers Leukemia Celgene Non Hodgkin Lymphoma Eisai Ezh2 Treatment Of Non Hodgkin Lymphoma

Is EPZM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 27.82
52 Week Low 9.735
Average Volume 831,905
200-Day Moving Average 17.01
50-Day Moving Average 17.14
20-Day Moving Average 17.94
10-Day Moving Average 18.38
Average True Range 1.19
ADX 15.11
+DI 21.78
-DI 24.81
Chandelier Exit (Long, 3 ATRs ) 16.18
Chandelier Exit (Short, 3 ATRs ) 18.77
Upper Bollinger Band 19.32
Lower Bollinger Band 16.57
Percent B (%b) 0.2
BandWidth 15.31
MACD Line 0.16
MACD Signal Line 0.24
MACD Histogram -0.0798
Fundamentals Value
Market Cap 1 Billion
Num Shares 58.5 Million
EPS -2.07
Price-to-Earnings (P/E) Ratio -8.27
Price-to-Sales 55.00
Price-to-Book 6.25
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.09
Resistance 3 (R3) 18.18 17.94 17.93
Resistance 2 (R2) 17.94 17.69 17.90 17.87
Resistance 1 (R1) 17.53 17.54 17.41 17.44 17.82
Pivot Point 17.30 17.30 17.24 17.25 17.30
Support 1 (S1) 16.89 17.05 16.77 16.80 16.42
Support 2 (S2) 16.65 16.90 16.61 16.37
Support 3 (S3) 16.24 16.65 16.31
Support 4 (S4) 16.15